Viewing data from:

TRETINOIN

ANDA

TRETINOIN | A075265 | PADAGIS US LLC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: RETIN-A(TE code: AB1)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 2 NDCs

Highest NADAC/Unit

$1.57

per gm

Lowest NADAC/Unit

$0.9284

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00574220520TRETINOIN 0.05% CREAM	$1.57	GM	Generic	—	2026-08-19
00574220545TRETINOIN 0.05% CREAM	$0.9284	GM	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$21.77

Highest Price

$40.83

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00574-2205-20TRETINOIN 0.05% CREAM,TOP	$21.77	FSS	Padagis Sourcing Solutions LLC	09/30/2026
00574-2205-45TRETINOIN 0.05% CREAM,TOP	$40.83	FSS	Padagis Sourcing Solutions LLC	09/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain6 active DMFs4 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

SIEGFRIED PHARMACHEMIKALIEN MINDEN GMBHTRETINOIN

DMF 34561978

OLON SPATRETINOIN

DMF 74741988

AMCOL HEALTH AND BEAUTY SOLUTIONS INCTRETINOIN 4% IN POLY-POREr POLYMER (TRETINOIN IN ALLYL METHACRYLATES CROSSPOLYMER)

DMF 231862009

OLON SPATRETINOIN TYPE 2

DMF 251922011

BIOPHORE INDIA PHARMACEUTICALS PVT LTDTRETINOIN

DMF 269222013

CHONGQING HUAPONT PHARMACEUTICAL CO LTDTRETINOIN

DMF 273982013

DSM NUTRITIONAL PRODUCTS LTDInactiveTRETINOIN (ALL-TRANS-RETINDE, ACID)

DMF 77341988

SHANGHAI NO 6 PHARMACEUTICAL FACTORYInactiveTRETINOIN

DMF 79961989

HOFFMANN LA ROCHE INCInactiveTRETINOIN CAPSULES

DMF 85921990

RANBAXY LABORATORIES LTDInactiveTRETINOIN USP (NON STERILE BULK)

DMF 244202010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Dec 24, 1998	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.05%

AB1

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Dec 24, 1998

No patent or exclusivity listings for this strength.